First Data on HIV-1 Resistance Mutations to Antiretroviral Drugs in Central African Republic

No abstract is available for this paper.

• Publication year

  2010

• Venue

  AIDS Research and Human Retroviruses

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/aid.2010.0091PMID 20939688
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence.

  2008cited by this paper
• Resistance and viral subtypes: how important are the differences and why do they occur?

  2007cited by this paper
• Impact of HIV-1 pol diversity on drug resistance and its clinical implications

  2006cited by this paper
• Increasing HIV Type 1 Polymorphic Diversity But No Resistance to Antiretroviral Drugs in Untreated Patients from Central African Republic: A 2005 Study

  2006cited by this paper
• Broad Spectrum of Coreceptor Usage and Rapid Disease Progression in HIV-1–Infected Individuals from Central African Republic

  2003cited by this paper
• Identification of a New Circulating Recombinant Form of HIV Type 1, CRF11-cpx, Involving Subtypes A, G, J, and CRF01-AE, in Central Africa

  2002cited by this paper
• Increase of HIV-1 subtype A in Central African Republic.

  1999cited by this paper
• A highly heterogeneous HIV-1 epidemic in the Central African Republic.

  1996cited by this paper

• Seroprevalence and molecular characterization of viral hepatitis and HIV co-infection in the Central African Republic

  2024cites this paper
• Seroprevalence and molecular characterization of viral hepatitis and HIV co-infection in the Central African Republic

  2023cites this paper
• High Resistance Mutation To cART In HIV-1 Exposed Infected Children And Recent Emergence Of CRF02_AG Variant In Bouar, A Rural Environment of Central African Republic

  2021cites this paper
• High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO

  2019cites this paper
• Trends of HIV Viral Load in Patients under Combined Antiretroviral Treatment in Bangui, Central African Republic

  2018cites this paper
• Update on HIV-1 acquired and transmitted drug resistance in Africa.

  2015cites this paper
• Favorable Therapeutic Response with an Antiretroviral Salvage Regimen in an HIV-1-Positive Subject Infected with a CRF11-cpx Virus

  2014cites this paper
• Adaptive HIV-Specific B Cell-Derived Humoral Immune Defenses of the Intestinal Mucosa in Children Exposed to HIV via Breast-Feeding

  2013cites this paper
• CRF22_01A1 is Involved in the Emergence of New HIV-1 Recombinants in Cameroon

  2012cites this paper
• Virological Response and Resistance Profiles After 18 to 30 Months of First- or Second-/Third-Line Antiretroviral Treatment: A Cross-Sectional Evaluation in HIV Type 1-Infected Children Living in the Central African Republic

  2012cites this paper
• Virological Response and Resistance Profiles After 24 Months of First-Line Antiretroviral Treatment in Adults Living in Bangui, Central African Republic

  2012cites this paper
• Prevalence, genetic diversity and antiretroviral drugs resistance-associated mutations among untreated HIV-1-infected pregnant women in Gabon, central Africa

  2012cites this paper